Cotrimoxazole (CTX) prophylaxis is recommended by the World Health Organisation for HIV infected persons. However, once HIV infected patients have commenced anti-retroviral treatment (ART), the benefits of continued CTX prophylaxis are not known. The COSTOP randomised controlled trial sought to assess the efficacy and safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults stabilized on ART in Uganda. This data collection contains 12 individual-level datasets associated with the study. It covers: time to the first clinical event; time to first grade 3-4 laboratory adverse event; Adherence to CTX, ART and ITN; all-cause mortality; all grade 3-4 haematological adverse events; laboratory parameters and CD4 counts at week 48; number of episodes of haematological grade 3-4 AEs; time to first hospital admission; and a sensitivity analysis.

The depositors confirm that the datasets have been fully anonymised and that ethics issues have been addressed prior to sharing. Queries will be handled by the following people: [1] Zacchaeus Anywaine; [2] Jonathan Levin; [3] Heiner Grosskurth; and [4] Ayoub Kakande.

Cotrimoxazole prophylaxis, HIV infections, HIV positive, Anti-retroviral treatment, Randomised controlled trial